Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)
Close on Nov 17, 2026Market cap $9.75BP/E –Yield –
Madrigal Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Madrigal Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was -25.3%. For fiscal 2025 it was -30.1%, against -258.6% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -30.1% | +228.6 |
| FY2024 | Dec 31, 2024 | -258.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -15.9% | +4.0 |
| Q1 FY2026 | Mar 31, 2026 | -30.3% | +23.0 |
| Q4 FY2025 | Dec 31, 2025 | -18.2% | +39.3 |
| Q3 FY2025 | Sep 30, 2025 | -39.8% | +132.3 |
| Q2 FY2025 | Jun 30, 2025 | -19.9% | +1018.3 |
| Q1 FY2025 | Mar 31, 2025 | -53.4% | – |
| Q4 FY2024 | Dec 31, 2024 | -57.5% | – |
| Q3 FY2024 | Sep 30, 2024 | -172.0% | – |
| Q2 FY2024 | Jun 30, 2024 | -1038.2% | – |
See a number that looks wrong?